<DOC>
	<DOC>NCT02552849</DOC>
	<brief_summary>This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and reporting observed predicted forced vital capacity (FVC) change from baseline on an ongoing basis.</brief_summary>
	<brief_title>Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>&gt; or = 18 years of age Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) Prescribed and/or currently taking Esbriet (pirfenidone) for the treatment of IPF Hypersensitivity to Esbriet (pirfenidone) Concomitant use of fluvoxamine Severe hepatic impairment or endstage liver disease Severe renal impairment or endstage renal disease requiring dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>